Schulze H, Isaacs J T, Senge T
Urologische Klinik, Ruhr-Universität Bochum, Marienhospital Herne, Bundesrepublik Deutschland.
Urologe A. 1988 Mar;27(2):105-10.
Presently, there is no effective therapy for increasing survival of metastatic prostatic cancer. New approaches to this major disease are, therefore, urgently needed. One approach is to study the biology of prostatic carcinogenesis in order to develop a therapeutic modality to prevent the development of clinically manifest prostatic cancer. Based upon international epidemiological data, it should be possible to lower the incidence of clinical prostatic cancer by more than 10-fold among the males of the western industrial states. An alternative approach is to study the tumor biology of prostatic cancer in order to identify new modalities to better treat already established clinical prostatic cancer. Such studies have already demonstrated that individual prostatic cancers are composed of clones of cancer cells which are phenotypically heterogeneous even before therapy is initiated. Due to this tumor cell heterogeneity, the direction of future studies should be towards combining androgen ablation plus chemotherapy early in the disease in order to affect both the androgen-dependent and -independent cancer cells present within individual prostatic cancers.
目前，对于提高转移性前列腺癌患者的生存率尚无有效的治疗方法。因此，迫切需要针对这一重大疾病的新方法。一种方法是研究前列腺癌发生的生物学机制，以便开发一种治疗方式来预防临床显性前列腺癌的发生。根据国际流行病学数据，西方工业国家的男性中临床前列腺癌的发病率应有可能降低10倍以上。另一种方法是研究前列腺癌的肿瘤生物学，以便确定更好地治疗已确诊的临床前列腺癌的新方法。此类研究已经表明，即使在开始治疗之前，单个前列腺癌也是由表型异质性的癌细胞克隆组成。由于这种肿瘤细胞异质性，未来的研究方向应该是在疾病早期将雄激素剥夺与化疗相结合，以影响单个前列腺癌中存在的雄激素依赖性和非依赖性癌细胞。
